NEW ORLEANS, Jan. 11, 2019 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc. (NasdaqGM: IMMU), if they purchased the Company’s shares between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Immunomedics investors should visit us at https://www.claimsfiler.com/cases/view-immunomedics-inc-securities-litigation-1 or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Immunomedics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 17, 2018, FDAnews.com reported in an article entitled “FDA Hits Immunomedics for Data Integrity Breach” that “the FDA cited Immunomedics for a host of violations-including its handling of a data integrity breach-observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” Then, on December 20, 2018, Favus Institutional Research issued a report further detailing the breach.
On this news, the price of Immunomedics’ shares plummeted.
The case is Odeh v. Immunomedics, Inc. et al., No. 2:18-cv-17645.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.